研究業績（原著論文のみ）/ Publications(Original Articles only)
2011年度
Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K.
Oncogene, 30(39): 4097-106, 2011.
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, Ercan D, Rogers A, Roncalli M, Takeda M, Fujisaka Y, Philips J, Shimizu T, Maenishi O, Cho Y, Sun J, Destro A, Taira K, Takeda K, Okabe T, Swanson J, Itoh H, Takada M, Lifshits E, Okuno K, Engelman JA, Shivdasani RA, Nishio K, Fukuoka M, Varella-Garcia M, Nakagawa K, Janne PA.
Sci Transl Med, 3(99): 99ra86, 2011.
Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells.
Arao T, Matsumoto K, Furuta K, Kudo K, Kaneda H, Nagai T, Sakai K, Fujita Y, Tamura D, Aomatsu K, Koizumi F, Nishio K.
Anticancer Res, 31(9): 2787-96, 2011.
Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer.
Kaneda H, Arao T, Matsumoto K, De Velasco MA, Tamura D, Aomatsu K, Kudo K, Sakai K, Nagai T, Fujita Y, Tanaka K, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K.
Br J Cancer, 105(8): 1210-7, 2011.
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Nishio M, Yamanaka T, Matsumoto K, Kimura H, Sakai K, Sakai A, Sone T, Horiike A, Koizumi F, Kasahara K, Ohira T, Ikeda N, Saijo N, Arao T, Nishio K.
J Thorac Oncol, 6(11): 1889-94, 2011.
Developments for a growing Japanese patient population: facilitating new technologies for future health care.
Kato H, Nishimura T, Ikeda N, Yamada T, Kondo T, Saijo N, Nishio K, Fujimoto J, Nomura M, Oda Y, Lindmark B, Maniwa J, Hibino H, Unno M, Ito T, Sawa Y, Tojo H, Egawa S, Edula G, Lopez M, Wigmore M, Inase N, Yoshizawa Y, Nomura F, Marko-Varga G.
J Proteomics, 74(6): 759-64, 2011.
Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
Takezawa K, Okamoto I, Okamoto W, Takeda M, Sakai K, Tsukioka S, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K.
Br J Cancer, 104(10): 1594-601, 2011.
Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo.
Kudo K, Arao T, Tanaka K, Nagai T, Furuta K, Sakai K, Kaneda H, Matsumoto K, Tamura D, Aomatsu K, De Velasco MA, Fujita Y, Saijo N, Kudo M, Nishio K.
Clin Cancer Res, 17(6): 1373-81, 2011.
FcgammaR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.
Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y.
Ann Oncol, 22(6): 1302-7, 2011.
Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells.
Okamoto W, Okamoto I, Arao T, Yanagihara K, Nishio K, Nakagawa K.
Br J Cancer, 105(3): 407-12, 2011.
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
Nagai T, Arao T, Furuta K, Sakai K, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Matsumoto K, Saijo N, Kudo M, Nishio K.
Mol Cancer Ther, 10(1): 169-77, 2011.
The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinoma.
Hagiwara S, Kudo M, Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park AM, Munakata H.
J Gastroenterol, 46(2): 212-21, 2011.
Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines.
Kashiwagi E, Izumi H, Yasuniwa Y, Baba R, Doi Y, Kidani A, Arao T, Nishio K, Naito S, Kohno K.
Cancer Sci, 102(2): 382-6, 2011.
Prospective study evaluating the plasma concentrations of twenty-six cytokines and response to morphine treatment in cancer patients.
Makimura C, Arao T, Matsuoka H, Takeda M, Kiyota H, Tsurutani J, Fujita Y, Matsumoto K, Kimura H, Otsuka M, Koyama A, Imamura CK, Yamanaka T, Tanaka K, Nishio K, Nakagawa K.
Anticancer Res, 31(12): 4561-8, 2011.
Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T.
Clin Cancer Res, 17(8): 2528-37, 2011.
Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
Takezawa K, Okamoto I, Nishio K, Janne PA, Nakagawa K.
Clin Cancer Res, 17(8): 2140-8, 2011.
Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Azuma K, Tsurutani J, Sakai K, Kaneda H, Fujisaka Y, Takeda M, Watatani M, Arao T, Satoh T, Okamoto I, Kurata T, Nishio K, Nakagawa K.
Biochem Biophys Res Commun, 407(1): 219-24, 2011.
Overexpression of cofilin 1 can predict progression-free survival in patients with epithelial ovarian cancer receiving standard therapy.
Nishimura S, Tsuda H, Kataoka F, Arao T, Nomura H, Chiyoda T, Susumu N, Nishio K, Aoki D.
Hum Pathol, 42(4): 516-21, 2011.
Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y, Katanasaka Y, Kitamura Y, Tsuda H, Nishio K, Tamura T, Koizumi F.
Breast Cancer Res, 13(3): R66, 2011.
What can and cannot be done using a microarray analysis? Treatment stratification and clinical applications in oncology.
Arao T, Matsumoto K, Maegawa M, Nishio K.
Biol Pharm Bull, 34(12): 1789-93, 2011.
2010年度
Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma.
Kasahara K, Arao T, Sakai K, Matsumoto K, Sakai A, Kimura H, Sone T, Horiike A, Nishio M, Ohira T, Ikeda N, Yamanaka T, Saijo N, Nishio K.
Clin Cancer Res, 16(18): 4616-24, 2010.
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors.
Okamoto I, Kaneda H, Satoh T, Okamoto W, Miyazaki M, Morinaga R, Ueda S, Terashima M, Tsuya A, Sarashina A, Konishi K, Arao T, Nishio K, Kaiser R, Nakagawa K.
Mol Cancer Ther, 9(10): 2825-33, 2010.
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Okamoto W, Okamoto I, Tanaka K, Hatashita E, Yamada Y, Kuwata K, Yamaguchi H, Arao T, Nishio K, Fukuoka M, Janne PA, Nakagawa K.
Mol Cancer Ther, 9(10): 2785-92, 2010.
KDR Kinase Inhibitor Isolated from the Mushroom Boletopsis leucomelas.
Kaneko A, Tsukada M, Fukai M, Suzuki T, Nishio K, Miki K, Kinoshita K, Takahashi K, Koyama K.
J Nat Prod, 73(5): 1002-4, 2010.
Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, Fukuoka M, Nishio K, Nakagawa K.
Mol Cancer Ther, 9(5): 1188-97, 2010.
FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.
Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K, Nishio K.
Cancer Res, 70(5): 2053-63, 2010.
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Takeda M, Okamoto I, Fujita Y, Arao T, Ito H, Fukuoka M, Nishio K, Nakagawa K.
J Thorac Oncol, 5(3): 399-400, 2010.
Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.
Tamura D, Arao T, Tanaka K, Kaneda H, Matsumoto K, Kudo K, Aomatsu K, Fujita Y, Watanabe T, Saijo N, Kotani Y, Nishimura Y, Nishio K.
Cancer Sci, 101(6): 1403-8, 2010.
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor
Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M, Nishio K, Nakagawa K.
Mol Cancer Ther, 9(6): 1647-56, 2010.
Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.
Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Janne PA, Nakagawa K.
Cancer Sci, 101(1): 167-72, 2010.
Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, Yamaguchi H, Nishio K, Nakagawa K.
Cancer Res, 70(24): 10402-10, 2010.
Role of ZNF143 in tumor growth through transcriptional regulation of DNA replication and cell-cycle-associated genes.
Izumi H, Wakasugi T, Shimajiri S, Tanimoto A, Sasaguri Y, Kashiwagi E, Yasuniwa Y, Akiyama M, Han B, Wu Y, Uchiumi T, Arao T, Nishio K, Yamazaki R, Kohno K.
Cancer Sci, 101(12): 2538-45, 2010.
Amplification of GNAS may be an independent, qualitative, and reproducible biomarker to predict progression-free survival in epithelial ovarian cancer.
Tominaga E, Tsuda H, Arao T, Nishimura S, Takano M, Kataoka F, Nomura H, Hirasawa A, Aoki D, Nishio K.
Gynecol Oncol, 118(2): 160-6, 2010.
Plasma concentrations of VCAM-1 and PAI-1: a predictive biomarker for post-operative recurrence in colorectal cancer
Yamada Y, Arao T, Matsumoto K, Gupta V, Tan W, Fedynyshyn J, Nakajima TE, Shimada Y, Hamaguchi T, Kato K, Taniguchi H, Saito Y, Matsuda T, Moriya Y, Akasu T, Fujita S, Yamamoto S, Nishio K.
Cancer Sci, 101(8): 1886-90, 2010.
Antiangiogenic metabolites from a marine-derived fungus, Hypocrea vinosa.
Ohkawa Y, Miki K, Suzuki T, Nishio K, Sugita T, Kinoshita K, Takahashi K, Koyama K.
J Nat Prod, 73(4): 579-82, 2010.
2009年度
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.
Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, Tamura D, Aomatsu K, Tamura T, Yamada Y, Saijo N, Nishio K.
Cancer Res, 69(18): 7160-4, 2009.
SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion.
Tanaka K, Arao T, Maegawa M, Matsumoto K, Kaneda H, Kudo K, Fujita Y, Yokote H, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K.
Int J Cancer, 124(5): 1072-80, 2009.
Epidermal growth factor receptor lacking C-terminal autophosphorylation sites retains signal transduction and high sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor.
Maegawa M, Arao T, Yokote H, Matsumoto K, Kudo K, Tanaka K, Kaneda H, Fujita Y, Ito F, Nishio K.
Cancer Sci, 100(3): 552-7, 2009.
Mitogen-activated protein kinase phosphatase-1 modulated JNK activation is critical for apoptosis induced by inhibitor of epidermal growth factor receptor-tyrosine kinase.
Takeuchi K, Shin-ya T, Nishio K, Ito F.
FEBS J, 276(5): 1255-65, 2009.
N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of kappaB kinase beta expression.
Hosoi F, Izumi H, Kawahara A, Murakami Y, Kinoshita H, Kage M, Nishio K, Kohno K, Kuwano M, Ono M.
Cancer Res, 69(12): 4983-91, 2009.
Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells.
Fukui T, Kodera Y, Nishio K, Masuda N, Tamura T, Koizumi F.
Cancer Sci, 100(6): 1137-43, 2009.
Osteopontin modulates malignant pleural mesothelioma cell functions in vitro.
Ohashi R, Tajima K, Takahashi F, Cui R, Gu T, Shimizu K, Nishio K, Fukuoka K, Nakano T, Takahashi K.
Anticancer Res, 29(6): 2205-14, 2009.
Role of multidrug resistance-associated protein 1 in the pathogenesis of allergic airway inflammation.
Yoshioka M, Sagara H, Takahashi F, Harada N, Nishio K, Mori A, Ushio H, Shimizu K, Okada T, Ota M, Ito YM, Nagashima O, Atsuta R, Suzuki T, Fukuda T, Fukuchi Y, Takahashi K.
Am J Physiol Lung Cell Mol Physiol, 296(1): L30-6, 2009.
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T, Okamoto I, Tsukioka S, Uchida J, Hatashita E, Yamada Y, Yoshida T, Nishio K, Fukuoka M, Janne PA, Nakagawa K.
Clin Cancer Res, 15(3): 907-13, 2009.
Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS.
Matsumoto K, Shimizu C, Arao T, Andoh M, Katsumata N, Kohno T, Yonemori K, Koizumi F, Yokote H, Aogi K, Tamura K, Nishio K, Fujiwara Y.
J Proteome Res, 8(2): 457-62, 2009.3
Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Watabe T, Shimoda Y, Arao T, Nishio K, Tamura T, Koizumi F.
J Thorac Oncol, 4(2): 208-13, 2009.
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.
Sekine I, Shimizu C, Nishio K, Saijo N, Tamura T.
Int J Clin Oncol, 14(2): 112-9, 2009.
EGFR mutation up-regulates EGR1 expression through the ERK pathway.
Maegawa M, Arao T, Yokote H, Matsumoto K, Kudo K, Tanaka K, Kaneda H, Fujita Y, Ito F, Nishio K.
Anticancer Res, 29(4): 1111-7, 2009.
2008年度
GFP image analysis in the mouse orthotopic bladder cancer model.
De Velasco MA, Tanaka M, Anai S, Tomioka A, Nishio K, Uemura H.
Oncol Rep, 20(3): 543-7, 2008.
EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line.
Fukai J, Yokote H, Yamanaka R, Arao T, Nishio K, Itakura T.
Mol Cancer Ther, 7(9): 2768-78, 2008.
Establishment and molecular profiling of a novel human pancreatic cancer panel for 5-FU.
Yanagihara K, Takigahira M, Tanaka H, Arao T, Aoyagi Y, Oda T, Ochiai A, Nishio K.
Cancer Sci, 99(9): 1859-64, 2008.
RPN2 gene confers docetaxel resistance in breast cancer.
Honma K, Iwao-Koizumi K, Takeshita F, Yamamoto Y, Yoshida T, Nishio K, Nagahara S, Kato K, Ochiya T.
Nat Med, 14(9): 939-48, 2008.
Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III.
Fukai J, Nishio K, Itakura T, Koizumi F.
Cancer Sci, 99(10): 2062-9, 2008.
Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples.
Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, Shimada Y, Hamaguchi T, Kato K, Hamano T, Koizumi F, Tamura T, Saito D, Shimoda T, Saka M, Fukagawa T, Katai H, Sano T, Sasako M, Nishio K.
Cancer Sci, 99(11): 2193-9, 2008.
Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia.
Nakayama T, Hieshima K, Arao T, Jin Z, Nagakubo D, Shirakawa AK, Yamada Y, Fujii M, Oiso N, Kawada A, Nishio K, Yoshie O.
Oncogene, 27(23): 3221-32, 2008.
Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T, Kawahara A, Basaki Y, Hattori S, Nakashima K, Nakano K, Shirouzu K, Kohno K, Yanagawa T, Yamana H, Nishio K, Ono M, Kuwano M, Kage M.
Cancer Res, 68(5): 1504-12, 2008.
Emerging ethnic differences in lung cancer therapy.
Sekine I, Yamamoto N, Nishio K, Saijo N.
Br J Cancer, 99(11): 1757-62, 2008.
Association of epidermal growth factor receptor (EGFR) gene mutations with EGFR amplification in advanced non-small cell lung cancer.
Morinaga R, Okamoto I, Fujita Y, Arao T, Sekijima M, Nishio K, Ito H, Fukuoka M, Kadota J, Nakagawa K.
Cancer Sci, 99(12): 2455-60, 2008.
N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor.
Matsumoto K, Yokote H, Arao T, Maegawa M, Tanaka K, Fujita Y, Shimizu C, Hanafusa T, Fujiwara Y, Nishio K.
Cancer Sci, 99(8): 1611-7, 2008.
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk.
Yoshida T, Okamoto I, Okabe T, Iwasa T, Satoh T, Nishio K, Fukuoka M, Nakagawa K.
Int J Cancer, 122(7): 1530-8, 2008.
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
Kiura K, Nakagawa K, Shinkai T, Eguchi K, Ohe Y, Yamamoto N, Tsuboi M, Yokota S, Seto T, Jiang H, Nishio K, Saijo N, Fukuoka M.
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.
2007年度
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M, Nakao S.
Br J Cancer, 97(6): 778-84, 2007.
Abrogation of the interaction between osteopontin and alphavbeta3 integrin reduces tumor growth of human lung cancer cells in mice.
Cui R, Takahashi F, Ohashi R, Gu T, Yoshioka M, Nishio K, Ohe Y, Tominaga S, Takagi Y, Sasaki S, Fukuchi Y, Takahashi K.
Lung Cancer, 57(3): 302-10, 2007.
Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K.
Cancer Sci, 98(9): 1498-503, 2007.
A possible relationship between the anti-cancer potency of photodynamic therapy using the novel photosensitizer ATX-s10-Na(II) and expression of the vascular endothelial growth factor in vivo.
Okunaka T, Usuda J, Ichinose S, Hirata H, Ohtani K, Maehara S, Inoue T, Imai K, Kubota M, Tsunoda Y, Kuroiwa Y, Tsutsui H, Furukawa K, Nishio K, Kato H.
Oncol Rep, 18(3): 679-83, 2007.
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Takeda M, Arao T, Yokote H, Komatsu T, Yanagihara K, Sasaki H, Yamada Y, Tamura T, Fukuoka K, Kimura H, Saijo N, Nishio K.
Clin Cancer Res, 13(10): 3051-7, 2007.
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
Sone T, Kasahara K, Kimura H, Nishio K, Mizuguchi M, Nakatsumi Y, Shibata K, Waseda Y, Fujimura M, Nakao S.
Cancer, 109(9): 1836-44, 2007.
Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review.
Sekine I, Minna JD, Nishio K, Saijo N, Tamura T.
Jpn J Clin Oncol, 37(5): 329-36, 2007.
Detection of epidermal growth factor receptor mutation in transbronchial needle aspirates of non-small cell lung cancer.
Horiike A, Kimura H, Nishio K, Ohyanagi F, Satoh Y, Okumura S, Ishikawa Y, Nakagawa K, Horai T, Nishio M.
Chest, 131(6): 1628-34, 2007.
Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines.
Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, Uramoto H, Sugio K, Yasumoto K, Sasaguri Y, Wang KY, Otsuji Y, Kohno K.
Oncogene, 26(33): 4749-60, 2007.
Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell.
Ohashi R, Takahashi F, Cui R, Yoshioka M, Gu T, Sasaki S, Tominaga S, Nishio K, Tanabe KK, Takahashi K.
Cancer Lett, 252(2): 225-34, 2007.
Prognostic implications of the nuclear localization of Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: their correlation with activated Akt, LRP/MVP and P-glycoprotein expression.
Oda Y, Ohishi Y, Basaki Y, Kobayashi H, Hirakawa T, Wake N, Ono M, Nishio K, Kuwano M, Tsuneyoshi M.
Cancer Sci, 98(7): 1020-6, 2007.
Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.
Morinaga R, Okamoto I, Furuta K, Kawano Y, Sekijima M, Dote K, Satou T, Nishio K, Fukuoka M, Nakagawa K.
Lung Cancer, 58(3): 411-3, 2007.
ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes.
Wakasugi T, Izumi H, Uchiumi T, Suzuki H, Arao T, Nishio K, Kohno K.
Oncogene, 26(36): 5194-203, 2007.
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.
Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K.
Cancer Sci, 98(8): 1275-80, 2007.
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
Marko-Varga G, Ogiwara A, Nishimura T, Kawamura T, Fujii K, Kawakami T, Kyono Y, Tu HK, Anyoji H, Kanazawa M, Akimoto S, Hirano T, Tsuboi M, Nishio K, Hada S, Jiang H, Fukuoka M, Nakata K, Nishiwaki Y, Kunito H, Peers IS, Harbron CG, South MC, Higenbottam T, Nyberg F, Kudoh S, Kato H.
J Proteome Res, 6(8): 2925-35, 2007.
Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells.
Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, Shimoyama T, Nishio K, Kuwano M.
Oncogene, 26(19): 2736-46, 2007.
Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
Mol Cancer Res, 5(4): 393-401, 2007.3
2006年度
Gefitinib efficacy associated with multiple expression of HER family in non-small cell lung cancer.
Nishio M, Taguchi F, Ohyanagi F, Horikike A, Ishikawa Y, Satoh Y, Okumura S, Nakagawa K, Nishio K, Horai T.
Anticancer Res, 26(5B): 3761-5, 2006.
Identification of expressed genes characterizing long-term survival in malignant glioma patients.
Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, Tanaka R, Sano M, Oide A, Sekijima M, Nishio K.
Oncogene, 25(44): 5994-6002, 2006.
Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, Kang YK, Nishio K, Fujiwara Y.
Breast Cancer Res Treat, 99(1): 9-17, 2006.
Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro.
Shimoyama T, Hamano T, Natsume T, Koizumi F, Kiura K, Tanimoto M, Nishio K.
Pharmacogenomics J, 6(6): 388-96, 2006.
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K.
Br J Cancer, 95(10): 1390-5, 2006.
EGFR mutation in various tissues.
Nishio K, Arao T, Kato T, Yokote H.
Cancer Chemotherapy and Pharmacology, 58: S39-S41, 2006.
Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.
Kato T, Nishio K.
Respirology, 11(6): 693-8, 2006.
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Kimura H, Kasahara K, Shibata K, Sone T, Yoshimoto A, Kita T, Ichikawa Y, Waseda Y, Watanabe K, Shiarasaki H, Ishiura Y, Mizuguchi M, Nakatsumi Y, Kashii T, Kobayashi M, Kunitoh H, Tamura T, Nishio K, Fujimura M, Nakao S.
J Thorac Oncol, 1(3): 260-7, 2006.
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Kimura H, Kasahara K, Kawaishi M, Kunitoh H, Tamura T, Holloway B, Nishio K.
Clin Cancer Res, 12(13): 3915-21, 2006.
High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients.
Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K.
Cancer Sci, 97(7): 642-8, 2006.
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Shimoyama T, Koizumi F, Fukumoto H, Kiura K, Tanimoto M, Saijo N, Nishio K.
Lung Cancer, 53(1): 13-21, 2006.
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.
Arao T, Yanagihara K, Takigahira M, Takeda M, Koizumi F, Shiratori Y, Nishio K.
Int J Cancer, 118(2): 483-9, 2006.
A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer.
Sekine I, Minna JD, Nishio K, Tamura T, Saijo N.
J Thorac Oncol, 1(1): 31-7, 2006.
Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.
Sakai K, Arao T, Shimoyama T, Murofushi K, Sekijima M, Kaji N, Tamura T, Saijo N, Nishio K.
FASEB J, 20(2): 311-3, 2006.
In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.
Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K.
Biochem J, 397(3): 537-43, 2006.
A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination.
Yanagihara K, Takigahira M, Takeshita F, Komatsu T, Nishio K, Hasegawa F, Ochiya T.
Cancer Res, 66(15): 7532-9, 2006.
Development and characterization of an antibody specifically recognizing a mutant EGFR (L858R) protein expressed frequently in non-small cell lung cancer.
Kawaishi M, Yokote H, Kimura H, Kasahara K, Nishio K.
Acta Med Kinki Univ, 31(2): 67-74, 2006.
Progress in the field of molecular biology and application of biotechnology to medical oncology.
Nishio K, Arao T.
Acta Med Kinki Univ, 31(2): 57-62, 2006.